Memorial Sloan Kettering Cancer Center
The researchers are doing this study to find out whether SX-682 in combination with proton craniospinal irradiation (pCSI) is a safe treatment approach for people with melanoma or non-small cell lung cancer (NSCLC) with leptomeningeal disease (LMD). The researchers will also look at whether the treatment combination is effective against participants' cancer.
Inclusion Criteria: * Age ≥ 18 * Written informed consent * ECOG 0-2 * Patients must have radiographic and/or pathologically confirmed leptomeningeal metastasis established through at least one of the following: * Positive CSF cytology for malignancy and/or positive CSF circulating tumor cells * CSF cytology with suspicious cells is considered positive; CSF cytology with atypical cells is considered equivocal and not positive * Unequivocal radiographic diagnosis of leptomeningeal metastasis on contrast- enhanced MRI * Patients may receive steroids to control symptoms related to CNS i…
Patients will receive SX-682 200 mg by mouth twice a day up to cycle 3. Subsequently, all patients will receive systemic therapy of the investigator's choice.
The total prescribed dose will be 30Gy (RBE) in 3Gy (RBE) daily fractions.